These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 27932607)

  • 1. Randomized, Open-Label, Phase 1/2a Study to Determine the Maximum Tolerated Dose of Intraventricular Sustained Release Nimodipine for Subarachnoid Hemorrhage (NEWTON [Nimodipine Microparticles to Enhance Recovery While Reducing Toxicity After Subarachnoid Hemorrhage]).
    Hänggi D; Etminan N; Aldrich F; Steiger HJ; Mayer SA; Diringer MN; Hoh BL; Mocco J; Faleck HJ; Macdonald RL;
    Stroke; 2017 Jan; 48(1):145-151. PubMed ID: 27932607
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Single-Dose Intraventricular Nimodipine Microparticles Versus Oral Nimodipine for Aneurysmal Subarachnoid Hemorrhage.
    Carlson AP; Hänggi D; Wong GK; Etminan N; Mayer SA; Aldrich F; Diringer MN; Schmutzhard E; Faleck HJ; Ng D; Saville BR; Bleck T; Grubb R; Miller M; Suarez JI; Proskin HM; Macdonald RL;
    Stroke; 2020 Apr; 51(4):1142-1149. PubMed ID: 32138631
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical Trial Protocol: Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy, and Safety Study Comparing EG-1962 to Standard of Care Oral Nimodipine in Adults with Aneurysmal Subarachnoid Hemorrhage [NEWTON-2 (Nimodipine Microparticles to Enhance Recovery While Reducing TOxicity After SubarachNoid Hemorrhage)].
    Hänggi D; Etminan N; Mayer SA; Aldrich EF; Diringer MN; Schmutzhard E; Faleck HJ; Ng D; Saville BR; Macdonald RL;
    Neurocrit Care; 2019 Feb; 30(1):88-97. PubMed ID: 30014184
    [TBL] [Abstract][Full Text] [Related]  

  • 4. NEWTON: Nimodipine Microparticles to Enhance Recovery While Reducing Toxicity After Subarachnoid Hemorrhage.
    Hänggi D; Etminan N; Macdonald RL; Steiger HJ; Mayer SA; Aldrich F; Diringer MN; Hoh BL; Mocco J; Strange P; Faleck HJ; Miller M
    Neurocrit Care; 2015 Oct; 23(2):274-84. PubMed ID: 25678453
    [TBL] [Abstract][Full Text] [Related]  

  • 5. NEWTON-2 Cisternal (Nimodipine Microparticles to Enhance Recovery While Reducing Toxicity After Subarachnoid Hemorrhage): A Phase 2, Multicenter, Randomized, Open-Label Safety Study of Intracisternal EG-1962 in Aneurysmal Subarachnoid Hemorrhage.
    Macdonald RL; Hänggi D; Ko NU; Darsaut TE; Carlson AP; Wong GK; Etminan N; Mayer SA; Aldrich EF; Diringer MN; Ng D; Strange P; Bleck T; Grubb R; Suarez JI
    Neurosurgery; 2020 Dec; 88(1):E13-E26. PubMed ID: 32985652
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Letter by Rustemi Regarding Article, "Randomized, Open-Label, Phase 1/2a Study to Determine the Maximum Tolerated Dose of Intraventricular Sustained Release Nimodipine for Subarachnoid Hemorrhage (NEWTON [Nimodipine Microparticles to Enhance Recovery While Reducing Toxicity After Subarachnoid Hemorrhage])".
    Rustemi O
    Stroke; 2017 Apr; 48(4):e113. PubMed ID: 28283604
    [No Abstract]   [Full Text] [Related]  

  • 7. Response by Hänggi and Macdonald to Letter Regarding Article, "Randomized, Open-Label, Phase 1/2a Study to Determine the Maximum Tolerated Dose of Intraventricular Sustained Release Nimodipine for Subarachnoid Hemorrhage (NEWTON [Nimodipine Microparticles to Enhance Recovery While Reducing Toxicity After Subarachnoid Hemorrhage])".
    Hänggi D; Macdonald RL
    Stroke; 2017 Apr; 48(4):e114. PubMed ID: 28283608
    [No Abstract]   [Full Text] [Related]  

  • 8. Nimodipine pharmacokinetics after intraventricular injection of sustained-release nimodipine for subarachnoid hemorrhage.
    Macdonald RL; Hänggi D; Strange P; Steiger HJ; Mocco J; Miller M; Mayer SA; Hoh BL; Faleck HJ; Etminan N; Diringer MN; Carlson AP; Aldrich F;
    J Neurosurg; 2021 Jan; 134(1):95-101. PubMed ID: 31812149
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravenous magnesium versus nimodipine in the treatment of patients with aneurysmal subarachnoid hemorrhage: a randomized study.
    Schmid-Elsaesser R; Kunz M; Zausinger S; Prueckner S; Briegel J; Steiger HJ
    Neurosurgery; 2006 Jun; 58(6):1054-65; discussion 1054-65. PubMed ID: 16723884
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized outcome study of enteral versus intravenous nimodipine in 171 patients after acute aneurysmal subarachnoid hemorrhage.
    Soppi V; Karamanakos PN; Koivisto T; Kurki MI; Vanninen R; Jaaskelainen JE; Rinne J
    World Neurosurg; 2012 Jul; 78(1-2):101-9. PubMed ID: 22120252
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intrathecal application of the nimodipine slow-release microparticle system eg-1962 for prevention of delayed cerebral ischemia and improvement of outcome after aneurysmal subarachnoid hemorrhage.
    Etminan N; Macdonald RL; Davis C; Burton K; Steiger HJ; Hänggi D
    Acta Neurochir Suppl; 2015; 120():281-6. PubMed ID: 25366637
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized, double-blind, vehicle-controlled trial of tirilazad mesylate in patients with aneurysmal subarachnoid hemorrhage: a cooperative study in North America.
    Haley EC; Kassell NF; Apperson-Hansen C; Maile MH; Alves WM
    J Neurosurg; 1997 Mar; 86(3):467-74. PubMed ID: 9046304
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Site-Specific, Sustained-Release Drug Delivery System for Aneurysmal Subarachnoid Hemorrhage.
    Hänggi D; Etminan N; Steiger HJ; Johnson M; Peet MM; Tice T; Burton K; Hudson B; Turner M; Stella A; Heshmati P; Davis C; Faleck HJ; Macdonald RL
    Neurotherapeutics; 2016 Apr; 13(2):439-49. PubMed ID: 26935204
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Poor Utilization of Nimodipine in Aneurysmal Subarachnoid Hemorrhage.
    Hajizadeh Barfejani A; Rabinstein AA; Wijdicks EFM; Clark SL
    J Stroke Cerebrovasc Dis; 2019 Aug; 28(8):2155-2158. PubMed ID: 31103551
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of nimodipine formulations and administration techniques via enteral feeding tubes in patients with aneurysmal subarachnoid hemorrhage: A multicenter retrospective cohort study.
    Mahmoud SH; Hefny FR; Panos NG; Delucilla L; Ngan Z; Perreault MM; Hamilton LA; Rowe AS; Buschur PL; Owusu-Guha J; Almohaish S; Sandler M; Armahizer MJ; Barra ME; Cook AM; Barthol CA; Hintze TD; Cantin A; Traeger J; Blunck JR; Shewmaker J; Burgess SV; Kaupp K; Brown CS; Clark SL; Wieruszewski ED; Tesoro EP; Ammar AA; Ammar MA; Binning MJ; Naydin S; Fox N; Peters DM; Mahmoud LN; Keegan SP; Brophy GM
    Pharmacotherapy; 2023 Apr; 43(4):279-290. PubMed ID: 36880540
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nimodipine Dose Reductions in the Treatment of Patients with Aneurysmal Subarachnoid Hemorrhage.
    Sandow N; Diesing D; Sarrafzadeh A; Vajkoczy P; Wolf S
    Neurocrit Care; 2016 Aug; 25(1):29-39. PubMed ID: 26690937
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of Locally Delivered Nimodipine Microparticles on Spreading Depolarization in Aneurysmal Subarachnoid Hemorrhage.
    Carlson AP; Alchbli A; Hänggi D; Macdonald RL; Shuttleworth CW
    Neurocrit Care; 2021 Feb; 34(1):345-349. PubMed ID: 32103439
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prospective, randomized, open-label phase II trial on concomitant intraventricular fibrinolysis and low-frequency rotation after severe subarachnoid hemorrhage.
    Etminan N; Beseoglu K; Eicker SO; Turowski B; Steiger HJ; Hänggi D
    Stroke; 2013 Aug; 44(8):2162-8. PubMed ID: 23735957
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Impact of Nimodipine Administration through Feeding Tube on Outcomes in Patients with Aneurysmal Subarachnoid Hemorrhage.
    Isse FA; Abdallah YEH; Mahmoud SH
    J Pharm Pharm Sci; 2020; 23(1):100-108. PubMed ID: 32348716
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of Early Versus Late Intravenous Followed by Oral Nimodipine Treatment on the Occurrence of Delayed Cerebral Ischemia Among Patients With Aneurysm Subarachnoid Hemorrhage.
    Samseethong T; Suansanae T; Veerasarn K; Liengudom A; Suthisisang C
    Ann Pharmacother; 2018 Nov; 52(11):1061-1069. PubMed ID: 29783859
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.